Last reviewed · How we verify
NCT03055286
Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
Phase 1, PHASE2 trial testing CWP232291 in Acute Myeloid Leukemia in 15 participants. Terminated before completion.
26 August 2025
Quick facts
| Lead sponsor | JW Pharmaceutical |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 6 February 2017 |
| Primary completion | 26 August 2025 |
| Estimated completion | 26 August 2025 |
| Sites | 5 locations across United States, South Korea |
Drugs / interventions tested
- CWP232291 — full drug profile →
Conditions studied
- Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
Sponsor
JW Pharmaceutical — full company profile →
Who can join
18 and older, any sex, with Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter (S. Korea/US), Phase Ib, open-label, dose-finding study to assess safety, PK, PD, and preliminary efficacy of CWP232291 administered in combination with ara-C in subjects with relapsed or refractory AML. The primary objectives in phase 2a is to assess the efficacy of CWP232291 administered in combination with cytarabine (response rate complete remission \[RR-CR\]/complete remission with incomplete blood count recovery \[CRi\]/partial remission \[PR\]).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting cancer stem cell pathways for cancer therapy.
Yang L, Shi P, Zhao G, Xu J, et al · · 2020 · cited 1354× · PMID 32296030 · DOI 10.1038/s41392-020-0110-5 -
Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents.
Zhou HM, Zhang JG, Zhang X, Li Q. · · 2021 · cited 305× · PMID 33589595 · DOI 10.1038/s41392-020-00430-1 -
WNT as a Driver and Dependency in Cancer.
Parsons MJ, Tammela T, Dow LE. · · 2021 · cited 202× · PMID 34518209 · DOI 10.1158/2159-8290.cd-21-0190 -
Wnt/β-Catenin Signaling: The Culprit in Pancreatic Carcinogenesis and Therapeutic Resistance.
Ram Makena M, Gatla H, Verlekar D, Sukhavasi S, et al · · 2019 · cited 127× · PMID 31480221 · DOI 10.3390/ijms20174242 -
Transcription Factors in Cancer Development and Therapy.
Vishnoi K, Viswakarma N, Rana A, Rana B. · · 2020 · cited 123× · PMID 32824207 · DOI 10.3390/cancers12082296 -
Characteristics of the cancer stem cell niche and therapeutic strategies.
Ju F, Atyah MM, Horstmann N, Gul S, et al · · 2022 · cited 84× · PMID 35659296 · DOI 10.1186/s13287-022-02904-1 -
New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression.
Bhatia S, Wang P, Toh A, Thompson EW. · · 2020 · cited 63× · PMID 32391381 · DOI 10.3389/fmolb.2020.00071 -
Wnt/β-catenin signaling pathway in uterine leiomyoma: role in tumor biology and targeting opportunities.
El Sabeh M, Saha SK, Afrin S, Islam MS, et al · · 2021 · cited 38× · PMID 33999334 · DOI 10.1007/s11010-021-04174-6
Verify or expand the search:
- PubMed search for NCT03055286
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Myeloid Leukemia
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
- NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
- NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
- NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting
Other JW Pharmaceutical trials
Trials by the same sponsor.
- NCT07514780 — To Evaluate the Safety, Pharmacokinetic and Pharmacodynamics of JW0061 in Healthy Volunteers · Phase 1 · not yet recruiting
- NCT07378098 — to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia · Phase 3 · recruiting
- NCT07374406 — To Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers · Phase 1 · recruiting
- NCT07442006 — Glycemic Variability of Combination Therapies in T2DM · Phase 4 · recruiting
- NCT07036458 — To Evaluate the Mass Balance Recovery, Metabolite Profile and Metabolite Identification in Healthy Male Subjects · Phase 1 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03055286 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by JW Pharmaceutical
- Last refreshed: 26 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03055286.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing